🇺🇸 FDA
Pipeline program

CAR-T cells chimeric antigen receptor T cells

IIT2025144

Phase 1 small_molecule active

Quick answer

CAR-T cells chimeric antigen receptor T cells for Relapsed/Refractory Acute Myeloid Leukemia(AML) is a Phase 1 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Relapsed/Refractory Acute Myeloid Leukemia(AML)
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials